David Zaccardelli, Verona CEO

Two years af­ter flop, Verona gets a win as it preps for piv­otal Phase III tri­als

Two years af­ter the lead for­mu­la­tion of Verona’s lead COPD drug whiffed in a Phase II study that knocked back their stock, an­oth­er for­mu­la­tion has hit across the board.

Verona said Tues­day that all four dos­es of an in­haler form of its com­pound en­sifen­trine sig­nif­i­cant­ly im­proved lung func­tion in a 40-per­son Phase II tri­al of the chron­ic con­di­tion. Most dos­es of the drug hit on all pri­ma­ry and sec­ondary end­points, with the ef­fect in­creas­ing with the dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.